Board Member at Neurocrine Biosciences, Inc.
Shalini Sharp has served on our Board of Directors since March 2021. From May 2012 until October 2020, Ms. Sharp served as Chief Financial Officer and Executive Vice President for Ultragenyx Pharmaceutical Inc., and from 2006 to 2012, she served as Chief Financial Officer of Agenus Inc. From 2003 to 2006, Ms. Sharp held increasing roles of responsibility at Agenus spanning strategic planning, corporate development, investor relations, corporate finance and business development. Prior to Agenus, Ms. Sharp held strategic planning and corporate finance roles and ultimately served as chief of staff to the chair of the board of directors at Elan Pharmaceuticals, from August 1998 to August 1999 and September 2001 to August 2003. Ms. Sharp also previously served as a management consultant at McKinsey & Company as well as an investment banker at Goldman Sachs, specializing in pharmaceuticals and medical devices. Ms. Sharp has served on the boards of directors of Neurocrine Biosciences since February 2020, Precision Biosciences since December 2018, Sutro Biopharma since November 2018, Organon and Co. since June 2021, and the TB Alliance (non-profit) since January 2015. Ms. Sharp previously served on the boards of directors of Panacea Acquisition Corporation from June 2020 to until it merged with Nuvation Bio in February 2021, Array Biopharma Inc. from April 2017 until its acquisition in July 2019, and Agenus from May 2012 to June 2018. Ms. Sharp received a B.A. from Harvard College and an M.B.A. from Harvard Business School.
Source: Mirati Therapeutics, Inc. on 04/15/2022
By accessing ExecAtlas, you can view bios, network, connections and references of industry leading executives like Shalini Sharp. More specifically, you'll be able to:
Access over 800,000 executive and board member profiles.
Example: Shalini Sharp